Humacyte Taps 25-Year Medtech Executive to Drive Symvess Launch, Dialysis BLA Push
Humacyte appointed industry veteran Jim Mercadante, who has launched over 50 medical products and generated millions in sales, as Chief Commercial Officer. He will lead sales, marketing and market access to scale the U.S. rollout of Symvess and advance the ATEV pipeline toward a dialysis BLA filing.
1. Chief Commercial Officer Appointment
Humacyte named Jim Mercadante as Chief Commercial Officer. Mercadante brings more than 25 years of medtech and healthcare experience, having launched over 50 products and driven millions of dollars in growth across major companies such as Abbott, Johnson & Johnson, GE and Qure.ai.
2. Strategic Commercial Leadership
In his new role, Mercadante will oversee all aspects of the company’s commercial strategy, including sales, marketing and market access. His mandate includes accelerating the U.S. expansion of Symvess and preparing for potential future indications in dialysis and other vascular applications.
3. Symvess Launch and Pipeline Progress
Symvess, Humacyte’s first FDA-approved acellular tissue engineered vessel for extremity vascular trauma, has secured hospital VAC approvals, inclusion in the U.S. Defense Logistics Agency catalog and initiated international filings in Israel. The company is advancing its ATEV pipeline, with a planned biologics license application for hemodialysis access and late-stage trials in peripheral artery disease.